EGFR-IN-139

EGFR-IN-139 (PD 18) is a potent and selective EGFR inhibitor effective against wild-type and mutant forms, including L858R/T790M. It demonstrates anticancer activity in vitro against EGFR-high cell lines like A549 and H1975, supporting its use in NSCLC research.